Nintedanib Goibela (Nintedanib)

Nintedanib blocks several receptor tyrosine kinases—VEGFR, PDGFR and FGFR—thereby reducing fibroblast activation, migration and transformation, and inhibiting new blood‑vessel formation. This dual antifibrotic and anti‑angiogenic effect underlies its therapeutic benefit in lung fibrosis and certain cancers.

The specific dose of Nintedanib Goibela is determined by the prescribing clinician based on the patient’s condition, weight, renal and hepatic function, and concomitant therapies. Physicians follow approved labeling and adjust the regimen as needed for safety and efficacy.

Safety data for nintedanib in pregnancy and lactation are limited, and the product is classified as contraindicated or not recommended for use in these situations. Women of child‑bearing potential should use effective contraception, and breastfeeding mothers should discuss alternatives with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

The primary alternative for idiopathic pulmonary fibrosis is pirfenidone, another antifibrotic agent. While both drugs aim to slow lung function decline, nintedanib targets multiple tyrosine kinases and has a broader anti‑angiogenic profile, whereas pirfenidone’s mechanism involves modulation of cytokine production. Choice between them depends on patient tolerance, comorbidities and physician judgment.

Nintedanib Goibela capsules should be stored at ambient temperature below 25 °C, in the original blister pack, protected from moisture and direct sunlight. Do not refrigerate or freeze the product, and keep it out of reach of children.

The medication is taken orally as a capsule, usually with food to minimise gastrointestinal discomfort. Patients should swallow the capsule whole with water and follow the dosing schedule prescribed by their clinician, without crushing or opening the capsule.

Serious adverse events include significant liver enzyme elevations, bleeding complications (especially when combined with anticoagulants), arterial thrombotic events, gastrointestinal perforation, severe infections and rare life‑threatening skin reactions. Patients should be monitored regularly for these risks and report any concerning symptoms promptly.

Nintedanib is contraindicated in patients with severe hepatic impairment (Child‑Pugh C), those who are pregnant or breastfeeding, and individuals with known hypersensitivity to nintedanib or any capsule excipients. Caution is also advised for patients with active bleeding, uncontrolled hypertension, or recent major surgery.